Agricultural Products and Services

Layn

Layn released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 446.87 M, actual EPS CNY 0.0573

Layn to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

Layn released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 771.68 M, actual EPS CNY 0.0874

Layn released FY2025 Annual Earnings on March 30 After-Market (BJT), actual revenue CNY 2.044 B (forecast CNY 2.005 B), actual EPS CNY 0.1945 (forecast CNY 0.22)

Layn to Release FY2025 Annual Earnings on March 31 After-Market (BJT), Forecast Revenue CNY 2.005 B, EPS CNY 0.22

Layn released FY2025 9 Months earnings on October 27 After-Market (BJT), actual revenue CNY 1.272 B, actual EPS CNY 0.1046

Layn released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 435.19 M, actual EPS CNY 0.0549

Layn to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

Layn released FY2025 Q2 earnings on August 28 After-Market BJT, actual revenue CNY 392.67 M, actual EPS CNY 0.0096

Layn released FY2025 Semi-Annual earnings on August 28 After-Market (BJT), actual revenue CNY 836.96 M, actual EPS CNY 0.05

Layn to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Leyie Biotech's Secretary Responds to US Factory Progress and Future Production Plans

Huaxin Securities Maintains Buy Rating on Lain Bio

Lyons Magnus Launches Multiple Products with 'Dietary Sugar Reduction' and 'Natural' Concepts

LYB Executives Plan to Reduce Shares

Huaxin Securities Gives BUY Rating to Lain Bio

Lyons Biotech Q1 2025 Revenue Up 30.21% YoY

Layn released FY2025 Q1 earnings on April 25 After-Market (BJT), actual revenue CNY 444.29 M, actual EPS CNY 0.04

Layn to Release FY2025 Q1 Earnings Report on April 26 After-Market BJT

Lyons Magnus Synthetic Biologics Facility Capacity Ramp-Up Expected to Contribute Revenue by 2025

002931

002166

300468

36Kr learned that the three major A-share indices opened mixed, with the Shanghai Composite Index down 0.08%, the Shenzhen Component Index down 0.1%, and the ChiNext Index up 0.11%; the concepts of artificial meat and stablecoins led the gains, with Layn approaching the daily limit and Forms Syntron rising over 3%; the lithium battery and precious metals sectors saw significant declines, with Huasen Lithium down over 4% and Hunan Silver down over 2%; new stock N Jiangtian surged 187.6% on its first day of listing, and Fenglong was suspended and then hit the daily limit

36Kr

Fenglong

Forms Syntron

The three major A-share indices opened mixed, with Fenglong hitting the daily limit after resuming trading

Layn: Mr. Qin Benjun is planning to change the company's control and intends to transfer part of his shares in the company to the counterparty through an agreement and waive the voting rights of some of his shares. The stock is suspended

Wallstreetcn

Layn announced that its revenue for the third quarter was 435 million yuan, a decrease of 2.09%; net profit was 32.2853 million yuan, a decrease of 12.10%. Revenue for the first three quarters was 1.272 billion yuan, an increase of 8.73%; net profit was 70.3953 million yuan, a decrease of 30.73%

Zhitong

Layn: Net profit in the third quarter was 32.2853 million yuan, a decrease of 12.10%

001283

On September 5th, a total of 2 listed companies had their restricted shares unlocked, with a total market value of approximately 2.07 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Layn 002166 Additional A Shares Original Shareholders' Allocation Listed 165 million HIGHPOWER TECHNOLOGY 001283 Pre-issuance Shares Restricted Circulation 22.7489 million

HIGHPOWER TECHNOLOGY

Zhitong A-share lock-up release overview | September 5

On August 19th, Layn stated on the interactive platform that in the domestic market, the draft for public consultation of the steviol glycoside RebM2, which the company has applied for as a new type of food additive, ended on August 14th, and the company is actively promoting its subsequent approval work; in the overseas market, the company's RebM2 passed the US FDA GRAS certification in February this year and can be legally sold in the US food and beverage market. The RebM2 product was exclusively developed by the company's R&D team and is expected to become a new profit growth point for the company in the future

Layn: The RebM2 product is expected to become a new profit growth point for the company in the future

600572

300026

600557

002020

300158

The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also rising

CONBA

Chase Sun

Kanion Pharmaceutical

JINGXIN

Zhendong Pharmacy

On May 29th, Layn stated on the investor interaction platform that the company has innovatively launched terminal beverages such as Zero Boundary Craft White Beer, Ginseng Pomegranate Drink, Ganoderma and Dendrobium Drink, and Luo Han Guo Flavored Water, focusing on the concepts of "sugar reduction" and "natural."

Layn: The company has launched terminal beverages such as Zero Boundary Craft White Beer and Ginseng Pomegranate Drink around the concepts of "sugar reduction" and "natural."

Layn announced that the company's chairman Xie Yongfu, vice president Bai Yu, chief financial officer Zheng Hui, and vice president Luo Huayang plan to reduce their holdings by a total of 1,018,500 shares, accounting for approximately 0.14% of the company's total share capital, within 3 months after the announcement is disclosed, during 15 trading days

Layn's certain directors and senior executives plan to reduce their holdings by no more than 0.14% of the shares

Layn announced that its revenue for the first quarter of 2025 was 444 million yuan, a year-on-year increase of 30.21%; net profit was 30.7949 million yuan, a year-on-year increase of 14.95%

Layn: In the first quarter of 2025, the net profit was 30.7949 million yuan, a year-on-year increase of 14.95%

Layn released its 2024 annual report, with operating revenue of 1.772 billion yuan, a year-on-year increase of 18.60%; net profit attributable to the parent company was 163 million yuan, a year-on-year increase of 97.56%. The net profit excluding non-recurring gains and losses was 151 million yuan, a year-on-year increase of 634.19%. Earnings per share were 0.22 yuan, and it plans to distribute a cash dividend of 1 yuan for every 10 shares. Revenue from the natural sweetener business was 951.9773 million yuan, and revenue from the tea extraction business was 182.2629 million yuan, both maintaining steady growth

Layn released its 2024 annual performance, with a net profit attributable to the parent company of 163 million yuan, a year-on-year increase of 97.56%

Layn(002166.SZ)